PARVOVIRUS B19 FINDS A DISEASE

@article{Cossart1981PARVOVIRUSBF,
  title={PARVOVIRUS B19 FINDS A DISEASE},
  author={Yvonne E. Cossart},
  journal={The Lancet},
  year={1981},
  volume={318},
  pages={988-989}
}
  • Y. Cossart
  • Published 31 October 1981
  • Medicine
  • The Lancet

Sicherheit von Blutprodukten – ein Update 2016

Aufgrund der Fortschritte in den letzten Jahren sind die Blutprodukte gegenwartig auf dem hochsten Sicherheitsstand der Medizingeschichte, sodass Ubertragungen of HCV oder HIV-1 kein medizinisch reales Risiko bei the Anwendung of Blut producekten mehr darstellen.

Parvovirus leading to thrombotic microangiopathy in a healthy adult

A healthy 47-year-old man initially presented with symptoms of body rash, myalgias, dark urine, nausea and vomiting, which warranted a kidney biopsy, which revealed micro thrombi in kidney vasculature, suggestive of thrombotic microangiopathy.

American society of Nephrology Quiz and Questionnaire 2014: transplantation.

The Nephrology Quiz and Questionnaire remains an extremely popular session for attendees of the Annual Kidney Week Meeting of the American Society of Nephrology and reproduces its educational value for the readers of CJASN.

Frequency of antiparvovírus B 19 antibodies in rheumatoid arthritis and systemic lupus erythematosus

It is demonstrated that the studied population is exposed to infection by B19, which demands attention with its manifestations, especially among patients at greatest risk, such as those immunosuppressed.

Human parvovirus B19: a review.

The present review looks at the nature of this virus with the view to provide more information about its biology, which may be useful to the present and future researchers.

Human parvovirus 4 in the blood supply and transmission by pooled plasma‐derived clotting factors: does it matter?

The paper by Sharp et al in this issue of Transfusion reports the transmission of human parvovirus 4 (PARV4) by “virus-inactivated” plasma pool-derived clotting factors, demonstrating that infection

References

SHOWING 1-8 OF 8 REFERENCES

Deanol in Gilles de la Tourette Syndrome: a preliminary investigation.

Deanol (dimethyl aminoethanol) is a putative cholinergic agonist and has reported effectiveness in conditions where there is a predominance of dopaminergic versus Cholinergic activity, e.g. levodopa-induced dyskinesias, neuroleptic induced tardive dyskinisia, and Huntington's chorea.

Emerging Treatments: Replacement Therapy with Choline or Lecithin in Neurological Diseases

  • A. Barbeau
  • Medicine, Psychology
    Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques
  • 1978
SUMMARY: This review evaluates the theoretical background and experimental data behind a new development: the replacement therapy of deficient central cholinergic systems with the dietary precursors

Cholinergic treatment in the Tourette syndrome.